ClinicalTrials.gg
CompletedNCT05633147Updated Jan 3, 2025Results posted

Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam

A Phase 1 interventional study of Linaprazan glurate and Drug drug interaction (DDI) - Clarithromycin (Part I) in Safety Issues, Pharmacokinetics and Drug Interaction, sponsored by Cinclus Pharma Holding AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Cinclus Pharma Holding AB · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a phase I, open-label, fixed sequence design, drug-drug-interaction (DDI) study divided in 2 parts. Part I is designed to evaluate whether concomitant treatment with linaprazan glurate and clarithromycin, a strong inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein P (PgP), leads to an effect on the systemic exposure to linaprazan glurate and linaprazan and whether there is an effect on the pharmacokinetics of clarithromycin after a single dose of linaprazan glurate. Part II is designed to evaluate the effect of repeated doses of linaprazan glurate on the pharmacokinetics (PK) of a sensitive substrate of CYP3A (midazolam).

02

Conditions studied

  • Safety Issues
  • Pharmacokinetics
  • Drug Interaction
  • Tolerability
03

In context

Lead sponsor

Cinclus Pharma Holding AB is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Willing and able to give written for participation in the study.
  2. Healthy male and female subjects of non- aged 18 to 60 years, inclusive.
  3. ≥ 18.0 and ≤ 30.0 kg/m2.
  4. Subjects as well as their partners, must agree to requirements. Male subjects must refrain from donating sperm.

Main Exclusion Criteria:

  1. Have known allergies to any components of the linaprazan glurate formulation, to clarithromycin/midazolam or to any drugs of a similar class including associated with any of the drugs.
  2. Use of inhibitors, antacids, PPIs or any medication that changes gastric pH.
  3. Use of any prescribed or non-prescribed CYP3A4-inducing medication or other metabolic enzyme inducers.
  4. History of any disease or disorder defined in the protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    linaprazan glurate

    Part I: Linaprazan glurate in base form, 100 mg once daily will be administered under fasting conditions at day 1 and day 10. Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice a day for 13 days. The morning dose will be administered under fasting conditions on Day 2 and Day 14.

    Drug: Linaprazan glurate · Drug: Drug drug interaction (DDI) - Clarithromycin (Part I) · Drug: Drug drug interaction (DDI) - Midazolam (Part 2)

Interventions

  • Investigational Medicinal Product: Linaprazan glurate (tablets). Part I: Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10. Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days.

  • DrugDrug drug interaction (DDI) - Clarithromycin (Part I)

    Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).

  • DrugDrug drug interaction (DDI) - Midazolam (Part 2)

    Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).

06

What researchers measure

Primary outcomes

  1. Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-inf

    Area under the plasma concentration curve from 0 to infinity (AUC0-inf). The AUC were calculated to the time point of the last quantifiable plasma concentration and then extrapolated to infinity using the concentration in the last quantifiable sample and the estimated terminal elimination rate constant (Lambdaz).

    Time frame: Timepoints collected: pre-dose, 15 min, 30 min, 45 min, 1.15 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 18 h, 24 h, 36 h, 48 h and 72 h after dosing (on dosing Days 1 and 10).

  2. Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-t

    AUC from time 0 to time t (AUC0-t). AUC0-t were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

    Time frame: Timepoints collected: pre-dose, 15 min, 30 min, 45 min, 1.15 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 18 h, 24 h, 36 h, 48 h and 72 h after dosing (on dosing Days 1 and 10).

  3. Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - Cmax

    Maximum plasma concentration (Cmax). Cmax were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

    Time frame: and 72 h after dosing (on dosing Days 1 and 10).

  4. Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-inf

    Area under the plasma concentration curve from 0 to infinity - AUCinf. AUC were calculated to the time point of the last quantifiable plasma concentration and then extrapolated to infinity using the concentration in the last quantifiable sample and the estimated terminal elimination rate constant (Lambdaz).

    Time frame: Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).

  5. Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-t

    AUC from time 0 to time t - AUC0-t. AUC0-t were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

    Time frame: Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).

  6. Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate - Cmax

    Maximum plasma concentration - Cmax. Cmax were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

    Time frame: Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).

07

Results

Posted Jan 3, 2025
Limitations and caveats
None reported

Participant flow

Subjects were recruited from CTC's database of volunteers and from advertising in media (including social media).

Participant flow — Overall Study
MilestonePeriod I, Part IPeriod II, Part II
Started1718
Completed1618
Not completed10

Outcome measures

PrimaryPeriod I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-inf

Area under the plasma concentration curve from 0 to infinity (AUC0-inf). The AUC were calculated to the time point of the last quantifiable plasma concentration and then extrapolated to infinity using the concentration in the last quantifiable sample and the estimated terminal elimination rate constant (Lambdaz).

Time frame:
Timepoints collected: pre-dose, 15 min, 30 min, 45 min, 1.15 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 18 h, 24 h, 36 h, 48 h and 72 h after dosing (on dosing Days 1 and 10).
Reported as:
Mean · h*nmol/L
Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-inf
h*nmol/LPart I
Linaprazan (alone)13950 ± 5649
Linaprazan (co-admin)42840 ± 16260
Linaprazan glurate (alone)137.3 ± 52.02
Linaprazan glurate (co-admin)165.9 ± 79.56
PrimaryPeriod I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-t

AUC from time 0 to time t (AUC0-t). AUC0-t were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

Time frame:
Timepoints collected: pre-dose, 15 min, 30 min, 45 min, 1.15 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 18 h, 24 h, 36 h, 48 h and 72 h after dosing (on dosing Days 1 and 10).
Reported as:
Mean · h*nmol/L
Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-t
h*nmol/LPart I
Linaprazan (alone)13870 ± 5346
Linaprazan (co-admin)39870 ± 13840
Linaprazan glurate (alone)133.6 ± 51.87
Linaprazan glurate (co-admin)160.6 ± 81.64
PrimaryPeriod I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - Cmax

Maximum plasma concentration (Cmax). Cmax were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

Time frame:
and 72 h after dosing (on dosing Days 1 and 10).
Reported as:
Mean · nmol/L
Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - Cmax
nmol/LPart I
Linaprazan (alone)1844 ± 712.4
Linaprazan (co-admin)2742 ± 1217
Linaprazan glurate (alone)131.1 ± 53.72
Linaprazan glurate (co-admin)176.8 ± 114.3
PrimaryPeriod II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-inf

Area under the plasma concentration curve from 0 to infinity - AUCinf. AUC were calculated to the time point of the last quantifiable plasma concentration and then extrapolated to infinity using the concentration in the last quantifiable sample and the estimated terminal elimination rate constant (Lambdaz).

Time frame:
Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).
Reported as:
Mean · h*ng/mL
Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-inf
h*ng/mLPart II
Midazolam (alone)38.57 ± 13.98
Midazolam (co-admin) Day 240.78 ± 16.04
Midazolam (co-admin) Day 1433.06 ± 10.46
PrimaryPeriod II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-t

AUC from time 0 to time t - AUC0-t. AUC0-t were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

Time frame:
Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).
Reported as:
Mean · h*ng/mL
Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate Administration - AUC0-t
h*ng/mLPart II
Midazolam (alone)37.12 ± 13.86
Midazolam (co-admin) Day 239.66 ± 16.01
Midazolam (co-admin) Day 1432.19 ± 10.41
PrimaryPeriod II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate - Cmax

Maximum plasma concentration - Cmax. Cmax were analyzed using a mixed model following a natural logarithmic transformation, with fixed effect for treatment and random effect for subject.

Time frame:
Timepoints collected: Pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 14 h, 20 h and 24 h (on day 1, 2 and 14).
Reported as:
Mean · ng/mL
Period II, Part II- Midazolam PK Parameters in the Presence and Absence of Linaprazan Glurate - Cmax
ng/mLPart II
Midazolam (alone)12.24 ± 4.091
Midazolam (co-admin) Day 213.69 ± 5.892
Midazolam (co-admin) Day 1413.53 ± 6.092

Adverse events

Collected over Period I, Part I: AEs (including SAEs) were collected from start of IMP administration (Day 1) until the end-of-study visit on Day 14. Period II, Part II: AEs (including SAEs) were collected from start of IMP administration (Day 1) until the end-of-study visit on Day 22.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I0/17 (0%)0/17 (0%)11/17 (64.7%)
Part II0/18 (0%)0/18 (0%)8/18 (44.4%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPart IPart II
HeadacheNervous system disorders3/172/18
DysgeusiaNervous system disorders2/170/18
FatigueGeneral disorders2/170/18
DiarrhoeaGastrointestinal disorders2/170/18
ErythemaSkin and subcutaneous tissue disorders2/170/18
Muscle contusionInjury, poisoning and procedural complications1/170/18
MalaiseGeneral disorders1/170/18
Abdominal pain upperGastrointestinal disorders1/171/18
Anal fissureGastrointestinal disorders1/170/18
Faeces softGastrointestinal disorders1/170/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part IPart IITotal
Mean37.5 ± 13.035.0 ± 12.336.2 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Part IPart IITotal
Female527
Male121628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part IPart IITotal
Hispanic or Latino112
Not Hispanic or Latino161733
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part IPart IITotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American112
White161531
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Part IPart IITotal
Sweden171835
08

Study locations

1 site
  • CTC Clinical Trials Consultants AB
    Uppsala, 75237, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in May 2023, 6 months.

Results were first posted in Jan 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Nov 27, 2022
Primary completionActual
May 30, 2023
CompletionActual
May 30, 2023
Results first posted
Jan 3, 2025
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05633147
Lead sponsor
Cinclus Pharma Holding AB
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Nov 27, 2022
Primary completion
May 30, 2023
Completion
May 30, 2023
Results posted
Jan 3, 2025
Last update
Jan 3, 2025

Study contacts

Karin Palm
study director · CTC Clinical Trial Consultants AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linaprazan glurate

Start the discussion